Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease
Identifieur interne : 001683 ( Istex/Corpus ); précédent : 001682; suivant : 001684Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease
Auteurs : Padraig E. O'Suilleabhain ; Teodoro Bottiglieri ; Richard B. Dewey Jr. ; Shailja Sharma ; Ramon Diaz-ArrastiaSource :
- Movement Disorders [ 0885-3185 ] ; 2004-12.
English descriptors
- KwdEn :
Abstract
Levodopa, typically ingested chronically at high daily doses, is predictably methylated by means of a series of reactions using B vitamins, which convert methionine to homocysteine. Elevated total plasma homocysteine (tHcy), a risk factor for dementia, has been found in PD patients using levodopa. We prospectively measured the effects on plasma tHcy and B vitamins of levodopa initiation, and measured the effects of dose changes and of treatment with dopamine agonists and entacapone. We collected paired plasma samples, at baseline and again after several months treatment, from patients initiating levodopa (n = 30), from patients whose levodopa dose was doubled (n = 15), halved or stopped (n = 14), from patients starting or stopping entacapone (n = 15) and from patients initiating or doubling dopamine agonist monotherapy (n = 16). Vitamin B12, folate, and tHcy concentrations were measured. Baseline tHcy concentration of 8.7 (2.8) μmol/L increased to 10.1 (3.1) μmol/L (P = 0.004) an average of 94 (range 36 to 200) days after initiation of 604 (240 to 1050) mg/day of L‐dopa. Average concentration of vitamin B12 fell from 380 to 291 pmol/ L (P = 0.01). Patients who doubled their daily levodopa dose experienced tHcy elevations from 9.5 to 11.1 μmol/L (P = 0.05). Levodopa reduction, agonist treatment, and entacapone treatment did not have significant effects. Levodopa elevates tHcy and lowers vitamin B12 concentration to modest degrees. The clinical implications, if any, have not yet been determined. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20253
Links to Exploration step
ISTEX:6D9F618F34471B9DE3E6C1EFD7741FE6F3E45D7ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease</title><author><name sortKey="O Suilleabhain, Padraig E" sort="O Suilleabhain, Padraig E" uniqKey="O Suilleabhain P" first="Padraig E." last="O'Suilleabhain">Padraig E. O'Suilleabhain</name><affiliation><mods:affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Bottiglieri, Teodoro" sort="Bottiglieri, Teodoro" uniqKey="Bottiglieri T" first="Teodoro" last="Bottiglieri">Teodoro Bottiglieri</name><affiliation><mods:affiliation>Baylor University Medical Center, Institute of Metabolic Disease, Dallas, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Dewey Jr, Richard B" sort="Dewey Jr, Richard B" uniqKey="Dewey Jr R" first="Richard B." last="Dewey Jr.">Richard B. Dewey Jr.</name><affiliation><mods:affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Sharma, Shailja" sort="Sharma, Shailja" uniqKey="Sharma S" first="Shailja" last="Sharma">Shailja Sharma</name><affiliation><mods:affiliation>Baylor University Medical Center, Institute of Metabolic Disease, Dallas, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Diaz Rrastia, Ramon" sort="Diaz Rrastia, Ramon" uniqKey="Diaz Rrastia R" first="Ramon" last="Diaz-Arrastia">Ramon Diaz-Arrastia</name><affiliation><mods:affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6D9F618F34471B9DE3E6C1EFD7741FE6F3E45D7A</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20253</idno><idno type="url">https://api.istex.fr/document/6D9F618F34471B9DE3E6C1EFD7741FE6F3E45D7A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001683</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease</title><author><name sortKey="O Suilleabhain, Padraig E" sort="O Suilleabhain, Padraig E" uniqKey="O Suilleabhain P" first="Padraig E." last="O'Suilleabhain">Padraig E. O'Suilleabhain</name><affiliation><mods:affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Bottiglieri, Teodoro" sort="Bottiglieri, Teodoro" uniqKey="Bottiglieri T" first="Teodoro" last="Bottiglieri">Teodoro Bottiglieri</name><affiliation><mods:affiliation>Baylor University Medical Center, Institute of Metabolic Disease, Dallas, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Dewey Jr, Richard B" sort="Dewey Jr, Richard B" uniqKey="Dewey Jr R" first="Richard B." last="Dewey Jr.">Richard B. Dewey Jr.</name><affiliation><mods:affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Sharma, Shailja" sort="Sharma, Shailja" uniqKey="Sharma S" first="Shailja" last="Sharma">Shailja Sharma</name><affiliation><mods:affiliation>Baylor University Medical Center, Institute of Metabolic Disease, Dallas, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Diaz Rrastia, Ramon" sort="Diaz Rrastia, Ramon" uniqKey="Diaz Rrastia R" first="Ramon" last="Diaz-Arrastia">Ramon Diaz-Arrastia</name><affiliation><mods:affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-12">2004-12</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1403">1403</biblScope><biblScope unit="page" to="1408">1408</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">6D9F618F34471B9DE3E6C1EFD7741FE6F3E45D7A</idno><idno type="DOI">10.1002/mds.20253</idno><idno type="ArticleID">MDS20253</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dopamine agonists</term><term>homocysteine</term><term>levodopa</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa, typically ingested chronically at high daily doses, is predictably methylated by means of a series of reactions using B vitamins, which convert methionine to homocysteine. Elevated total plasma homocysteine (tHcy), a risk factor for dementia, has been found in PD patients using levodopa. We prospectively measured the effects on plasma tHcy and B vitamins of levodopa initiation, and measured the effects of dose changes and of treatment with dopamine agonists and entacapone. We collected paired plasma samples, at baseline and again after several months treatment, from patients initiating levodopa (n = 30), from patients whose levodopa dose was doubled (n = 15), halved or stopped (n = 14), from patients starting or stopping entacapone (n = 15) and from patients initiating or doubling dopamine agonist monotherapy (n = 16). Vitamin B12, folate, and tHcy concentrations were measured. Baseline tHcy concentration of 8.7 (2.8) μmol/L increased to 10.1 (3.1) μmol/L (P = 0.004) an average of 94 (range 36 to 200) days after initiation of 604 (240 to 1050) mg/day of L‐dopa. Average concentration of vitamin B12 fell from 380 to 291 pmol/ L (P = 0.01). Patients who doubled their daily levodopa dose experienced tHcy elevations from 9.5 to 11.1 μmol/L (P = 0.05). Levodopa reduction, agonist treatment, and entacapone treatment did not have significant effects. Levodopa elevates tHcy and lowers vitamin B12 concentration to modest degrees. The clinical implications, if any, have not yet been determined. © 2004 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Padraig E. O'Suilleabhain MB, BCh</name><affiliations><json:string>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</json:string></affiliations></json:item><json:item><name>Teodoro Bottiglieri PhD</name><affiliations><json:string>Baylor University Medical Center, Institute of Metabolic Disease, Dallas, Texas, USA</json:string></affiliations></json:item><json:item><name>Richard B. Dewey Jr. MD</name><affiliations><json:string>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</json:string></affiliations></json:item><json:item><name>Shailja Sharma PhD</name><affiliations><json:string>Baylor University Medical Center, Institute of Metabolic Disease, Dallas, Texas, USA</json:string></affiliations></json:item><json:item><name>Ramon Diaz‐Arrastia MD, PhD</name><affiliations><json:string>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonists</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>homocysteine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Levodopa, typically ingested chronically at high daily doses, is predictably methylated by means of a series of reactions using B vitamins, which convert methionine to homocysteine. Elevated total plasma homocysteine (tHcy), a risk factor for dementia, has been found in PD patients using levodopa. We prospectively measured the effects on plasma tHcy and B vitamins of levodopa initiation, and measured the effects of dose changes and of treatment with dopamine agonists and entacapone. We collected paired plasma samples, at baseline and again after several months treatment, from patients initiating levodopa (n = 30), from patients whose levodopa dose was doubled (n = 15), halved or stopped (n = 14), from patients starting or stopping entacapone (n = 15) and from patients initiating or doubling dopamine agonist monotherapy (n = 16). Vitamin B12, folate, and tHcy concentrations were measured. Baseline tHcy concentration of 8.7 (2.8) μmol/L increased to 10.1 (3.1) μmol/L (P = 0.004) an average of 94 (range 36 to 200) days after initiation of 604 (240 to 1050) mg/day of L‐dopa. Average concentration of vitamin B12 fell from 380 to 291 pmol/ L (P = 0.01). Patients who doubled their daily levodopa dose experienced tHcy elevations from 9.5 to 11.1 μmol/L (P = 0.05). Levodopa reduction, agonist treatment, and entacapone treatment did not have significant effects. Levodopa elevates tHcy and lowers vitamin B12 concentration to modest degrees. The clinical implications, if any, have not yet been determined. © 2004 Movement Disorder Society</abstract><qualityIndicators><score>6.109</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1551</abstractCharCount><pdfWordCount>3193</pdfWordCount><pdfCharCount>19875</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>243</abstractWordCount></qualityIndicators><title>Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>19</volume><pages><total>6</total><last>1408</last><first>1403</first></pages><issn><json:string>0885-3185</json:string></issn><issue>12</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1002/mds.20253</json:string></doi><id>6D9F618F34471B9DE3E6C1EFD7741FE6F3E45D7A</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/6D9F618F34471B9DE3E6C1EFD7741FE6F3E45D7A/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/6D9F618F34471B9DE3E6C1EFD7741FE6F3E45D7A/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6D9F618F34471B9DE3E6C1EFD7741FE6F3E45D7A/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2004</date></publicationStmt><notesStmt><note>Robert and Ruth Glaze Foundation</note><note>National Institutes of Health - No. RO1 AG17861; No. UO1 HD42652; No. P30 AG12300; No. RO3 MH64889;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease</title><author><persName><forename type="first">Padraig E.</forename><surname>O'Suilleabhain</surname><roleName type="degree">MB, BCh</roleName></persName><note type="correspondence"><p>Correspondence: 5323 Harry Hines Blvd., Dallas, TX 75390‐9036</p></note><affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</affiliation></author><author><persName><forename type="first">Teodoro</forename><surname>Bottiglieri</surname><roleName type="degree">PhD</roleName></persName><affiliation>Baylor University Medical Center, Institute of Metabolic Disease, Dallas, Texas, USA</affiliation></author><author><persName><forename type="first">Richard B.</forename><surname>Dewey Jr.</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</affiliation></author><author><persName><forename type="first">Shailja</forename><surname>Sharma</surname><roleName type="degree">PhD</roleName></persName><affiliation>Baylor University Medical Center, Institute of Metabolic Disease, Dallas, Texas, USA</affiliation></author><author><persName><forename type="first">Ramon</forename><surname>Diaz‐Arrastia</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-12"></date><biblScope unit="vol">19</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1403">1403</biblScope><biblScope unit="page" to="1408">1408</biblScope></imprint></monogr><idno type="istex">6D9F618F34471B9DE3E6C1EFD7741FE6F3E45D7A</idno><idno type="DOI">10.1002/mds.20253</idno><idno type="ArticleID">MDS20253</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2004</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Levodopa, typically ingested chronically at high daily doses, is predictably methylated by means of a series of reactions using B vitamins, which convert methionine to homocysteine. Elevated total plasma homocysteine (tHcy), a risk factor for dementia, has been found in PD patients using levodopa. We prospectively measured the effects on plasma tHcy and B vitamins of levodopa initiation, and measured the effects of dose changes and of treatment with dopamine agonists and entacapone. We collected paired plasma samples, at baseline and again after several months treatment, from patients initiating levodopa (n = 30), from patients whose levodopa dose was doubled (n = 15), halved or stopped (n = 14), from patients starting or stopping entacapone (n = 15) and from patients initiating or doubling dopamine agonist monotherapy (n = 16). Vitamin B12, folate, and tHcy concentrations were measured. Baseline tHcy concentration of 8.7 (2.8) μmol/L increased to 10.1 (3.1) μmol/L (P = 0.004) an average of 94 (range 36 to 200) days after initiation of 604 (240 to 1050) mg/day of L‐dopa. Average concentration of vitamin B12 fell from 380 to 291 pmol/ L (P = 0.01). Patients who doubled their daily levodopa dose experienced tHcy elevations from 9.5 to 11.1 μmol/L (P = 0.05). Levodopa reduction, agonist treatment, and entacapone treatment did not have significant effects. Levodopa elevates tHcy and lowers vitamin B12 concentration to modest degrees. The clinical implications, if any, have not yet been determined. © 2004 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>levodopa</term></item><item><term>dopamine agonists</term></item><item><term>homocysteine</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-01-02">Received</change><change when="2004-03-26">Registration</change><change when="2004-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/6D9F618F34471B9DE3E6C1EFD7741FE6F3E45D7A/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/mds.v19:12</doi><numberingGroup><numbering type="journalVolume" number="19">19</numbering><numbering type="journalIssue">12</numbering></numberingGroup><coverDate startDate="2004-12">December 2004</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="20" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20253</doi><idGroup><id type="unit" value="MDS20253"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2004 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2004-01-02"></event><event type="manuscriptRevised" date="2004-03-10"></event><event type="manuscriptAccepted" date="2004-03-26"></event><event type="firstOnline" date="2004-07-21"></event><event type="publishedOnlineFinalForm" date="2004-10-27"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2004-07-21"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1403</numbering><numbering type="pageLast">1408</numbering></numberingGroup><correspondenceTo>5323 Harry Hines Blvd., Dallas, TX 75390‐9036</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20253.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="24"></count><count type="wordTotal" number="3619"></count></countGroup><titleGroup><title type="main" xml:lang="en">Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease</title><title type="short" xml:lang="en">Levodopa Increases Homocysteine</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Padraig E.</givenNames><familyName>O'Suilleabhain</familyName><degrees>MB, BCh</degrees></personName><contactDetails><email>padraig.osuilleabhain@utsouthwestern.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Teodoro</givenNames><familyName>Bottiglieri</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Richard B.</givenNames><familyName>Dewey</familyName><nameSuffix>Jr.</nameSuffix><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Shailja</givenNames><familyName>Sharma</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Ramon</givenNames><familyName>Diaz‐Arrastia</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Baylor University Medical Center, Institute of Metabolic Disease, Dallas, Texas, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">levodopa</keyword><keyword xml:id="kwd2">dopamine agonists</keyword><keyword xml:id="kwd3">homocysteine</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword></keywordGroup><fundingInfo><fundingAgency>Robert and Ruth Glaze Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>National Institutes of Health</fundingAgency><fundingNumber>RO1 AG17861</fundingNumber><fundingNumber>UO1 HD42652</fundingNumber><fundingNumber>P30 AG12300</fundingNumber><fundingNumber>RO3 MH64889</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Levodopa, typically ingested chronically at high daily doses, is predictably methylated by means of a series of reactions using B vitamins, which convert methionine to homocysteine. Elevated total plasma homocysteine (tHcy), a risk factor for dementia, has been found in PD patients using levodopa. We prospectively measured the effects on plasma tHcy and B vitamins of levodopa initiation, and measured the effects of dose changes and of treatment with dopamine agonists and entacapone. We collected paired plasma samples, at baseline and again after several months treatment, from patients initiating levodopa (n = 30), from patients whose levodopa dose was doubled (n = 15), halved or stopped (n = 14), from patients starting or stopping entacapone (n = 15) and from patients initiating or doubling dopamine agonist monotherapy (n = 16). Vitamin B12, folate, and tHcy concentrations were measured. Baseline tHcy concentration of 8.7 (2.8) μmol/L increased to 10.1 (3.1) μmol/L (<i>P</i> = 0.004) an average of 94 (range 36 to 200) days after initiation of 604 (240 to 1050) mg/day of <sc>L</sc>‐dopa. Average concentration of vitamin B12 fell from 380 to 291 pmol/ L (<i>P</i> = 0.01). Patients who doubled their daily levodopa dose experienced tHcy elevations from 9.5 to 11.1 μmol/L (<i>P</i> = 0.05). Levodopa reduction, agonist treatment, and entacapone treatment did not have significant effects. Levodopa elevates tHcy and lowers vitamin B12 concentration to modest degrees. The clinical implications, if any, have not yet been determined. © 2004 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Levodopa Increases Homocysteine</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Padraig E.</namePart><namePart type="family">O'Suilleabhain</namePart><namePart type="termsOfAddress">MB, BCh</namePart><affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</affiliation><description>Correspondence: 5323 Harry Hines Blvd., Dallas, TX 75390‐9036</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Teodoro</namePart><namePart type="family">Bottiglieri</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Baylor University Medical Center, Institute of Metabolic Disease, Dallas, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard B.</namePart><namePart type="family">Dewey Jr.</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Shailja</namePart><namePart type="family">Sharma</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Baylor University Medical Center, Institute of Metabolic Disease, Dallas, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ramon</namePart><namePart type="family">Diaz‐Arrastia</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2004-12</dateIssued><dateCaptured encoding="w3cdtf">2004-01-02</dateCaptured><dateValid encoding="w3cdtf">2004-03-26</dateValid><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">24</extent><extent unit="words">3619</extent></physicalDescription><abstract lang="en">Levodopa, typically ingested chronically at high daily doses, is predictably methylated by means of a series of reactions using B vitamins, which convert methionine to homocysteine. Elevated total plasma homocysteine (tHcy), a risk factor for dementia, has been found in PD patients using levodopa. We prospectively measured the effects on plasma tHcy and B vitamins of levodopa initiation, and measured the effects of dose changes and of treatment with dopamine agonists and entacapone. We collected paired plasma samples, at baseline and again after several months treatment, from patients initiating levodopa (n = 30), from patients whose levodopa dose was doubled (n = 15), halved or stopped (n = 14), from patients starting or stopping entacapone (n = 15) and from patients initiating or doubling dopamine agonist monotherapy (n = 16). Vitamin B12, folate, and tHcy concentrations were measured. Baseline tHcy concentration of 8.7 (2.8) μmol/L increased to 10.1 (3.1) μmol/L (P = 0.004) an average of 94 (range 36 to 200) days after initiation of 604 (240 to 1050) mg/day of L‐dopa. Average concentration of vitamin B12 fell from 380 to 291 pmol/ L (P = 0.01). Patients who doubled their daily levodopa dose experienced tHcy elevations from 9.5 to 11.1 μmol/L (P = 0.05). Levodopa reduction, agonist treatment, and entacapone treatment did not have significant effects. Levodopa elevates tHcy and lowers vitamin B12 concentration to modest degrees. The clinical implications, if any, have not yet been determined. © 2004 Movement Disorder Society</abstract><note type="funding">Robert and Ruth Glaze Foundation</note><note type="funding">National Institutes of Health - No. RO1 AG17861; No. UO1 HD42652; No. P30 AG12300; No. RO3 MH64889; </note><subject lang="en"><genre>Keywords</genre><topic>levodopa</topic><topic>dopamine agonists</topic><topic>homocysteine</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>1403</start><end>1408</end><total>6</total></extent></part></relatedItem><identifier type="istex">6D9F618F34471B9DE3E6C1EFD7741FE6F3E45D7A</identifier><identifier type="DOI">10.1002/mds.20253</identifier><identifier type="ArticleID">MDS20253</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2004 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001683 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001683 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:6D9F618F34471B9DE3E6C1EFD7741FE6F3E45D7A
|texte= Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |